|
|
|
|
 |
|||
|
|||
Volume 52 (6): 821-831, 2004
Copyright ©The Histochemical Society, Inc.
Tissue Distribution of the Death Ligand TRAIL and Its Receptors
Departments of Medical Oncology (DCS,EGdV,JJK,SdJ), Hematology (EV), Gynecology (FAvdH), Gastroenterology (JJK), and Pathology (JW,HH), University Hospital Groningen, Groningen, The Netherlands
Correspondence to: E.G.E. de Vries, MD, PhD, Dept. of Medical Oncology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. E-mail: e.g.e.de.vries{at}int.azg.nl
Recombinant human (rh) TNF-related apoptosis-inducing ligand (TRAIL) harbors potential as an anticancer agent. RhTRAIL induces apoptosis via the TRAIL receptors TRAIL-R1 and TRAIL-R2 in tumors and is non-toxic to nonhuman primates. Because limited data are available about TRAIL receptor distribution, we performed an immunohistochemical (IHC) analysis of the expression of TRAIL-R1, TRAIL-R2, the anti-apoptotic TRAIL receptor TRAIL-R3, and TRAIL in normal human and chimpanzee tissues. In humans, hepatocytes stained positive for TRAIL and TRAIL receptors and bile duct epithelium for TRAIL, TRAIL-R1, and TRAIL-R3. In brains, neurons expressed TRAIL-R1, TRAIL-R2, TRAIL-R3 but no TRAIL. In kidneys, TRAIL-R3 was negative, tubuli contorti expressed TRAIL-R1, TRAIL-R2, and TRAIL, and cells in Henle's loop expressed only TRAIL-R2. Heart myocytes showed positivity for all proteins studied. In colon, TRAIL-R1, TRAIL-R2, and TRAIL were present. Germ and Leydig cells were positive for all proteins studied. Endothelium in liver, heart, kidney, and testis lacked TRAIL-R1 and TRAIL-R2. In alveolar septa and bronchial epithelium TRAIL-R2 was expressed, brain vascular endothelium expressed TRAIL-R2 and TRAIL-R3, and in heart vascular endothelium only TRAIL-R3 was present. Only a few differences were observed between human and chimpanzee liver, brain, and kidney. In contrast to human, chimpanzee bile duct epithelium lacked TRAIL, TRAIL-R1, and TRAIL-R3, lung and colon showed no TRAIL or its receptors, TRAIL-R3 was absent in germ and Leydig cells, and vascular endothelium showed only TRAIL-R2 expression in the brain. In conclusion, comparable expression of TRAIL and TRAIL receptors was observed in human and chimpanzee tissues. Lack of liver toxicity in chimpanzees after rhTRAIL administration despite TRAIL-R1 and TRAIL-R2 expression is reassuring for rhTRAIL application in humans.
(J Histochem Cytochem 52:821–831, 2004)
Key Words: TRAIL • TRAIL-R1 • TRAIL-R2 • TRAIL-R3 • human • chimpanzee
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Yada, M. Yazawa, S. Ishida, H. Yoshida, K. Ichikawa, S. Kurakata, and K. Fujiwara A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes Ann. Onc., June 1, 2008; 19(6): 1060 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lorz, A. Benito-Martin, A. Boucherot, A. C. Ucero, M. P. Rastaldi, A. Henger, S. Armelloni, B. Santamaria, C. C. Berthier, M. Kretzler, et al. The Death Ligand TRAIL in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2008; 19(5): 904 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. O'Brien, M. A. Richardson, D. T. Berg, B. Gerlitz, A. Gupta, and B. W. Grinnell The Puzzling Role of TRAIL in Endothelial Cell Biology Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): e5 - e6. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Plummer, G. Attard, S. Pacey, L. Li, A. Razak, R. Perrett, M. Barrett, I. Judson, S. Kaye, N. L. Fox, et al. Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers Clin. Cancer Res., October 15, 2007; 13(20): 6187 - 6194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bin, J. Thorburn, L. R. Thomas, P. E. Clark, R. Humphreys, and A. Thorburn Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding J. Biol. Chem., September 21, 2007; 282(38): 28189 - 28194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Keogh, L. K. Harris, A. Freeman, P. N. Baker, J. D. Aplin, G. StJ. Whitley, and J. E. Cartwright Fetal-Derived Trophoblast Use the Apoptotic Cytokine Tumor Necrosis Factor-{alpha}-Related Apoptosis-Inducing Ligand to Induce Smooth Muscle Cell Death Circ. Res., March 30, 2007; 100(6): 834 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G.E. de Vries, J. A. Gietema, and S. de Jong Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications Clin. Cancer Res., April 15, 2006; 12(8): 2390 - 2393. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Ganten, R. Koschny, J. Sykora, H. Schulze-Bergkamen, P. Buchler, T. L. Haas, M. B. Schader, A. Untergasser, W. Stremmel, and H. Walczak Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs Clin. Cancer Res., April 15, 2006; 12(8): 2640 - 2646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Berent-Maoz, A. M. Piliponsky, I. Daigle, H.-U. Simon, and F. Levi-Schaffer Human Mast Cells Undergo TRAIL-Induced Apoptosis J. Immunol., February 15, 2006; 176(4): 2272 - 2278. [Abstract] [Full Text] [PDF]
|
|
| Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact |